70 results about "Brain Thrombus" patented technology

The invention discloses a thrombolysis prediction method based on deep learning and multi-modal fusion, and belongs to the technical field of thrombolysis prediction, and the method comprises the steps: S1, collecting an MRI image of a patient with ischemic cerebral apoplexy, and constructing a cerebral apoplexy automatic segmentation model; s2, carrying out image registration; s3, lesion segmentation; and S4, thrombolysis prediction. According to the cerebral apoplexy automatic segmentation model based on the gating parallel Mama network, the long-distance dependency relationship in the image can be effectively captured, ischemic cerebral apoplexy lesions can be rapidly and accurately segmented, and the lesion identification efficiency and accuracy are greatly improved; according to the algorithm provided by the invention, the linear time complexity is realized, the computing resource consumption is greatly reduced, and the bottleneck of the prior art is broken through; according to the cerebral apoplexy thrombolysis prediction model based on the multi-modal data, scientific automatic decision support is provided for judging whether the patient is suitable for thrombolysis treatment or not, and the quality and safety of medical decision are improved.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a targeted liposome as an active component in preparation of a medicine for treating ischemic brain injury. The targeted lipidosome for treating cerebral arterial thrombosis is prepared by fusing the lipidosome and the platelet-neutrophil aggregate membrane, realizes efficient and specific targeting of an ischemic brain region, effectively reduces brain tissue infarction and damage of a new region, relieves brain inflammation through multi-channel regulation and control, and improves the cerebral arterial thrombosis treatment effect. The compound can be used as an active ingredient for preparing a medicine for treating ischemic brain injury. And after the target liposome is further coated with a rutin drug, the synergistic treatment effect is realized. The liposome medicine can be used as an active component and has a good application prospect in treatment of ischemic brain injury diseases.

The invention provides an ergosterol-loaded brain-targeted nano preparation and a preparation method and application thereof, and relates to the field of nano materials and nano biological medicine.The active ingredient ergosterol of the nano preparation is entrapped in a DSPE-PEG-pinacol borate nano material, and the nano material has the ROS response characteristic and can be used for preparing a brain-targeted nano preparation. The ergosterol-loaded nano preparation is in the shape of a regular sphere, is uniform in particle size, has good dispersibility and stability, has good ability of targeted therapy of cerebral arterial thrombosis diseases, effectively solves the problems of poor targeting property, low bioavailability and the like of common drugs, enhances the therapeutic effect of ergosterol on cerebral arterial thrombosis, and has good application prospects. The ergosterol can effectively improve brain injury caused by the cerebral arterial thrombosis and has a good treatment effect, meanwhile, the ergosterol serving as the active ingredient plays a role in treating the cerebral arterial thrombosis by activating a PI3K / AKT / mTOR pathway, and a new direction is provided for treatment of the cerebral arterial thrombosis.

The invention belongs to the technical field of biomedical materials, and particularly relates to a photothermal nano-drug containing a guanidyl structure as well as a preparation method and application of the photothermal nano-drug, and the photothermal nano-drug is CA-COFBT-TG (at) TS obtained by taking COFBT-TG containing guanidyl as a carrier, loading a photothermal agent TS and then modifying a fibrin targeting peptide CA on the surface. The photo-thermal nano-drug is a covalent organic framework material platform, can be enriched at a thrombus part, has excellent photo-thermal conversion performance, can effectively remove thrombus at a focus part, and can improve neuronal death after cerebral arterial thrombosis by inhibiting ferroptosis.

The invention discloses an application of a polypeptide in preparation of a medicine for preventing or treating cerebral apoplexy. The polypeptide comprises an amino acid sequence as shown in SEQ ID NO: 1. The N15 polypeptide expressed by the sequence can inhibit apoptosis and autophagy of damaged neurons by inhibiting expression of Tom20 and PARP proteins, promote expression of SYN-1 protein to promote a patient with ischemic cerebral apoplexy to recover learning, memory and cognitive functions, can comprehensively protect neuronal damage caused by ischemic cerebral apoplexy, can promote recovery of damaged nerve cells of an OGD model, and has a good application prospect. The polypeptide has an obvious protection effect on neuronal cells, the polypeptide is connected with a cell transmembrane carrier and can penetrate through a blood brain barrier to enter brain tissue to directly act on the neuronal cells, and an ischemic cerebral apoplexy animal model verifies that the polypeptide has an effect of treating cerebral apoplexy. Particularly, the cognitive ability and learning and memory ability of a mouse with cerebral arterial thrombosis can be recovered to a normal level, and a good treatment effect on cerebral arterial thrombosis is achieved.

The invention relates to the technical field of biological medicine, in particular to a cerium oxide nano-enzyme delivery system based on carried neutrophil, and the system comprises cerium oxide nano-particles; the surfaces of the cerium oxide nanoparticles are coated with the lipoic acid zwitterionic polymer layers; the sialic acid molecules and the protocatechuic aldehyde molecules are modified on the surface of the lipoic acid zwitterionic polymer layer; wherein the system realizes breakthrough of a blood brain barrier and precise delivery of ischemic lesions through mediation targeting delivery of L-selectin on the surface of neutrophile granulocyte, and based on a cerium oxide nano-enzyme delivery system carrying neutrophile granulocyte, a'antioxidation-anti-inflammation-angiogenesis promotion-neural restoration 'quadruple synergistic mechanism is integrated, so that the system has the advantages that the system is simple in structure and convenient to use, and the application prospect is wide. And a new strategy of multi-target intervention is provided for cerebral arterial thrombosis treatment.

The invention provides novel application of gastrodin, and belongs to the technical field of biological medicine. By constructing an MCAO model of cerebral arterial thrombosis and detecting the influence of GAS on MCAO mouse and OGD-induced microglial cell ferroptosis, it is found that GAS alleviates the ferroptosis of cerebral arterial thrombosis, it is found through molecular docking and cell thermal displacement experiments that GAS is specifically bound with Alkbh5, the stability of protein is improved, nuclear translocation of Alkbh5 is promoted, and the GAS can be used for treating cerebral arterial thrombosis. Therefore, the methylation level of N6-methyladenosine (m6A) of a glutamic acid-cysteine ligase modified subunit (Gclm) is reduced, the expression of the Gclm is increased, the synthesis of glutathione is enhanced, and finally ferroptosis of microglial cells is inhibited. Therefore, the gastrodin can be used for preparing the medicine for treating the ferroptosis of the cerebral arterial thrombosis, and a new natural medicine source is provided for preventing and treating the ferroptosis of the cerebral arterial thrombosis.

Disclosed in the present invention is the use of a mesenchymal-stem-cell-derived intracellular nanovesicle in neuroprotection. Compared to a small extracellular vesicle with exosomes as the main component, the small intracellular nanovesicle of the present invention has a smaller particle size, a narrower particle size distribution range, and greater stability at different temperatures, and has good tissue compatibility. The small intracellular nanovesicle of the present invention can better ameliorate nerve injury or neurodegenerative diseases such as optic nerve injury, ischemic stroke and Alzheimer's disease, and has very good application and research value in the field of pharmaceuticals.

The invention relates to the technical field of medicines, in particular to application of DP-b99 and a derivative thereof in preparation of a medicine for treating cerebral ischemia mechanical thrombus extraction reperfusion injury. On the basis of mechanical thrombus extraction and reperfusion of cerebral ischemia, DP-b99 is combined to reduce mechanical thrombus extraction and reperfusion injury of cerebral arterial thrombosis, so that the inflammation level of brain tissues can be reduced, the volume of cerebral infarction can be reduced, the injury of the brain tissues can be effectively reduced, and the treatment effect is remarkable.

The invention belongs to the technical field of biological medicines, and particularly discloses a self-assembled nano preparation coated with a macrophage membrane as well as a preparation method and application of the self-assembled nano preparation. According to the nano preparation, nano particles formed by self-assembly of epigallocatechin gallate (EGCG), ferric chloride (FeCl3) and edaravone (EDV) serve as a core, and the outer layer of the nano preparation is coated with a macrophage membrane. The preparation method is a one-pot method and comprises the following steps: mixing and self-assembling EGCG, FeCl3 and EDV in a phosphate buffer solution, carrying out centrifugal purification, and carrying out ultrasonic fusion with a macrophage membrane. The nano preparation is uniform in particle size, has excellent free radical scavenging capacity and antioxidant activity, can effectively pass through a blood-brain barrier and target a cerebral ischemia reperfusion injury area, and shows a remarkable effect in preparation of drugs for treating cerebral arterial thrombosis.

The invention relates to the technical field of fusion membrane nano preparations, and provides a nano preparation capable of being used for cerebral arterial thrombosis gene drug targeted delivery, which comprises lipid-calcium phosphate nanoparticles, which are composed of DOPA modified calcium phosphate cores and lipidosome and are used for providing positive charges to obtain efficient gene loading efficiency and proton sponge effect, the intracellular efficient delivery and release of the gene are realized; and the exosome membrane is prepared from a cell culture solution extracted from bone marrow-derived mesenchymal stem cells and is used for improving the transfection efficiency of the carried medicine. According to the present invention, by using the process characteristic that the inner layer phospholipid and the outer layer phospholipid are not synchronously prepared during the LCP preparation process, the biological membrane of the exosome and the LCP outer layer phospholipid are fused during the LCP preparation of the outer layer phospholipid so as to construct the fusion membrane preparation having the characteristics of the biological membrane and capable of carrying out AMD3100 targeting modification, such that the advantages of the biological membrane and the AMD3100 in the targeting delivery system are combined so as to achieve the target delivery effect; and the bottleneck of drug delivery for brain diseases is solved.

The invention provides a method for quantifying a water content ratio, which comprises the following steps of: scanning a brain by using first energy and second energy through dual-energy CT (Computed Tomography) equipment to generate plain scanning data of each voxel; setting the three substances of the dual-energy tomography three-substance separation mathematical model as water, grey matter and white matter; processing the plain scanning data of each voxel by using the dual-energy tomography three-substance separation mathematical model to obtain enhanced data of each voxel; and calculating the water content percentage of each voxel according to the enhancement data of each voxel. The method for quantifying the water content can quantify the water content of the encephaledema tissue of the acute stroke patient, and further quantify the edema proportion of the encephaledema tissue. The invention further provides a water content ratio quantifying device, a tomography system and a storage medium which relate to the method.

The invention provides a selective KCNQ channel opener and application of the selective KCNQ channel opener in pharmacy. According to the invention, a series of KCNQ channel openers with high selectivity are obtained by carrying out structural modification and activity and selectivity evaluation on a KCNQ2 agonist 124-A10 (CAS number: 1173735-00-6) obtained by screening. Compared with common KCNQ channel openers, such as retigabine, ICA27243 and the like, the subtype selectivity of the compounds is enhanced, so that some toxic and side effects generated in the application of pharmaceutical preparations due to poor selectivity can be effectively avoided. The invention also provides applications of the compounds in preparation of anti-epileptic drugs, anti-schizophrenia drugs, anti-depression drugs and drugs for treating cerebral arterial thrombosis diseases, and provides more effective choices for treatment of related diseases.

The invention relates to application of peroxidase reductase 1 as a target spot in preparation of an IS treatment medicine, and belongs to the technical field of biological medicine. The method comprises the steps of high-sensitivity blood immune proteome map construction, large-scale independent queue longitudinal correlation verification, cross-racial and multi-tissue causal correlation verification, targeted experiment verification and mechanism exploration, target druggability evaluation, treatment potential confirmation and the like, and selects immune response proteins with significant differences between patients and controls. The immune response protein strongly related to the onset risk of the cerebral arterial thrombosis (IS) is further screened from plasma, cerebrospinal fluid and brain tissue samples, and finally the cerebral arterial thrombosis traditional Chinese medicine target peroxide reductase 1 (PRDX1) is found. A drug, such as a PRDX1 agonist or overexpression PRDX1, designed aiming at the drug target can effectively improve the progress of the IS disease.

The invention belongs to the technical field of gene drugs, and particularly relates to application of lncRNA-AU020206 in preparation of drugs for treating cerebral arterial thrombosis, the key effect of the lncRNA-AU020206 in occurrence and development of the cerebral arterial thrombosis is disclosed for the first time, and it is clear that the lncRNA-AU020206 activates ferroptosis signal channels through negative regulation of SLC7A11 expression, so that cerebral ischemia reperfusion injury is aggravated. In-vivo and in-vitro experiments prove that the levels of MDA, ROS and Fe < 2 + > can be remarkably reduced by silencing the lncRNA-AU020206, the expression of GPX4 and SLC7A11 can be up-regulated, the cerebral infarction volume and neurological dysfunction can be reduced, and cerebral edema and apoptosis can be improved. Therefore, the lncRNA-AU020206 not only can be used as a new target for treating the cerebral arterial thrombosis, but also can be used for developing a related diagnostic kit, and has remarkable clinical application prospect and market value.

The invention discloses application of Nrsn1 in preparation of a medicine for differentiating neural stem cells into neuronal cells, and belongs to the technical field of neurobiology. The invention provides application of Nrsn1 in preparation of a medicine for differentiating neural stem cells into neuronal cells. The invention relates to application of Nrsn1 in preparation of drugs for preventing and / or treating cerebral arterial thrombosis or neurodegenerative diseases. It is found that the Nrsn1 gene can promote the neural stem cells to be differentiated into neurons, and the efficiency of differentiating the neural stem cells into the neurons is improved.

The invention discloses an application of an Mbtps1 gene and a protein SKI-1 coded by the Mbtps1 gene in screening or preparing a medicine for treating cerebral arterial thrombosis, and particularly discloses an application of the Mbtps1 gene / protein SKI-1 as a medicine target of cerebral arterial thrombosis. A tMCAO mouse model is constructed by specifically knocking out a microglial cell Mbtps1 gene / protein SKI-1 of a tMCAO mouse to verify that the Mbtps1 gene and the protein SKI-1 can be used as drug targets for screening or preparing drugs for treating cerebral arterial thrombosis; the compound PF429242 is screened out and has the functions of repairing brain injury nerves caused by cerebral arterial thrombosis, inhibiting neuroinflammation and repairing fragmentation of a mitochondrial network, namely, the feasibility of the Mbtps1 gene and the protein SKI-1 serving as targets in screening or preparing medicines for preventing or treating cerebral arterial thrombosis is verified.

The invention discloses application of Ptbp2 in diagnosis and prognosis of cerebral arterial thrombosis. It is found for the first time that Ptbp2 can be used for early diagnosis of cerebral arterial thrombosis, and the Ptbp2 also has a good prediction effect on prognosis of cerebral arterial thrombosis patients. According to the present invention, the verification results of the collected real clinical samples show that the Ptbp2 has good effects of cerebral arterial thrombosis diagnosis and prognosis prediction, and has high accuracy, high sensitivity and high specificity. The invention provides a new thought and strategy for the technical field of cerebral arterial thrombosis diagnosis and prognosis prediction, and has important scientific significance and clinical application value.

This invention discloses a brain-targeting neutrophil membrane-encapsulated tanshinone IIa PLGA nanoparticle formulation, its preparation method, and its uses. The brain-targeting tanshinone IIa nanoparticle formulation, Neu-Tan-IIa@PLGA, is characterized by comprising a PLGA-loaded tanshinone IIa nanoparticle core (Tan-IIa@PLGA) and an outer neutrophil membrane coating. This invention effectively overcomes the problems of poor water solubility, low oral bioavailability, and difficulty in crossing the blood-brain barrier associated with tanshinone IIa. This invention provides a tanshinone IIa with strong targeting and high drug stability, enabling delivery to lesions in ischemic brain regions and improving the safety and efficacy of stroke treatment.

The invention discloses a kit for screening cerebral arterial thrombosis risk and a screening method, and belongs to the technical field of biological detection. The kit for screening the cerebral arterial thrombosis risk is a kit for detecting gene mutation of a C677T site of an MTHFR gene and comprises a forward primer and a reverse primer, the sequence of the forward primer is shown as SEQ ID NO.1, and the sequence of the reverse primer is shown as SEQ ID NO.2. The kit for screening the cerebral arterial thrombosis risk is a kit for detecting gene mutation of the C677T site of the MTHFR gene. The invention creatively finds that the gene polymorphism of the C677T site of the MTHFR gene has certain relevance with the disease of the cerebral arterial thrombosis, the site mutation is one of high-risk factors of the cerebral arterial thrombosis, and the A1298C site mutation of the MTHFR gene is not obviously associated with the susceptibility of the cerebral arterial thrombosis. The risk of the cerebral arterial thrombosis is evaluated by screening a susceptibility gene locus, the operation is simple, the cost is reduced, the prevention of the cerebral arterial thrombosis is enhanced, and the incidence rate of the cerebral arterial thrombosis is further reduced.

The invention discloses application of lncRNA-DCST1-AS1 in preparation of a medicine for treating cerebral arterial thrombosis, and relates to the technical field of biomedicine. The invention finds that after expression of lncRNA-DCST1-AS1 is up-regulated, the activity of neurons subjected to hypoglycemia and hypoxia reperfusion can be further inhibited, and neuronal injury and apoptosis are promoted. By down-regulating and intervening the lncRNA-DCST1-AS1, the occurrence of cerebral ischemia / reperfusion injury can be avoided, and the lncRNA-DCST1-AS1 has an obvious protection effect on neuronal injury caused by sugar deficiency and hypoxia reperfusion, can obviously improve the cell activity and reduce the cell apoptosis caused by the neuronal injury, can be applied to preparation of the medicine for treating cerebral arterial thrombosis, and has a very good application prospect.

The present invention discloses a Lactobacillus rhamnosus for improving thrombosis and stroke, and its products and applications, and relates to the field of microbial technology. The Lactobacillus rhamnosus (Lacticaseibacillus rhamnosus) NHNK‑604 disclosed in the present invention has been deposited in the China Center for Type Culture Collection on March 7, 2024, and its deposit number is CCTCC NO: M 2024417. NHNK‑604 has the functions of dissolving thrombus, regulating endothelial cell coagulation factors, reducing endothelial cell inflammation and apoptosis, reducing aging damage of brain microvascular endothelial cells, and promoting blood-brain barrier. In addition, bacterial biofilm can increase the colonization of mucin and intestinal epithelial cells, and can be used to prepare products for improving thrombosis and stroke.

The utility model discloses a rehabilitation training device for cerebral arterial thrombosis patient in the technical field of cerebral arterial thrombosis patient rehabilitation, which comprises bed plates, a pedal frame and a lifting mechanism, the bottom end of the bed plate is provided with a bottom plate, the top end of the bed plate is provided with a first support plate, and the side wall of one end of the first support plate is provided with a buffer mechanism; a pedal frame is installed at one end of the buffer mechanism, hand tension training mechanisms are installed on the side walls of the two sides of the bed plate, a third through hole is formed in the top end of the bed plate, a lifting mechanism is hinged to the interior of the third through hole, a third supporting plate is installed on the side wall of one end of the bottom plate, and an electric lifting rod is installed at the top end of the third supporting plate. A pull ring is pulled by a hand to drive a binding rope to ascend and descend in a second through hole and pull a gravity block, and through the design of the gravity block, rehabilitation training can be conveniently conducted on the hand of a patient through the weight of the gravity block.

The invention belongs to the technical field of cerebral apoplexy treatment medicine research, and particularly relates to a nano delivery system and application thereof. The nano delivery system is prepared according to the following steps: modifying cationic starch spheres with mitochondrial targeting peptide, loading PDK4-IN-1, and carrying out self-assembly to obtain an inner core; the preparation method comprises the following steps: modifying aminated anionic starch with homing peptide, and loading carfilzomib to form a starch spiral shell; and mixing the inner core with the starch spiral shell, and self-assembling to form the nano drug delivery system. According to the invention, a three-targeting, double-controlled-release and double-drug nano drug delivery system is constructed and is accurately delivered to a matrix action site in cytoplasm or mitochondria, so that double-channel synergistic enhancement of IS mitochondrial autophagy and toxicity attenuation and synergistic treatment of IS are realized.

The invention discloses a method for establishing a new atrial fibrillation mouse model with cerebral arterial thrombosis, and belongs to the field of medicine. The method comprises the following treatment steps for mice: (1) cerebral ischemia treatment; (2) behavioral evaluation; (3) normally feeding the mice of which the behavioral evaluation shows that the modeling is successful for 3 days; (4) measuring the threshold stimulation of the mouse after the step (3); and (5) performing programmed electrical stimulation to induce atrial fibrillation. The cerebral arterial thrombosis new atrial fibrillation mouse model established by the method is stable, reliable, high in success rate, low in cost and short in modeling time; compared with other models, the model provided by the invention can restore atrial fibrillation induced by a pathological model (cerebral ischemia) of human beings, does not need wearable equipment, and only needs common electrocardiogram detection.

The present invention relates to the technical field of cell therapy. Specifically disclosed are a mesenchymal stromal cell-based drug and a use thereof in the treatment of acute cerebral infarction. The present invention provides a cell-based drug, comprising mesenchymal stromal cells and a pharmaceutically acceptable excipient. Compared with stem cells, the mesenchymal stromal cells have a negative expression level of mRNA encoding self-renewal and differentiation in the mesenchymal stromal cells. The mesenchymal stromal cells account for 90% or more of the cell-based drug. The cell-based drug exhibits the characteristics and mechanism of action of stromal cells, homes to the neovasculature formed by endothelial cells at the injury site within an effective time window, plays a role in promoting / maintaining the neovasculature and remodeling the microenvironment of the injury site, fully ensures the safety and effectiveness of disease treatment, and provides a novel method for the diagnosis and treatment of related diseases.

The invention discloses a targeted delivery preparation as well as a preparation method and application thereof, and belongs to the technical field of biology and new medicine. The targeted delivery preparation comprises an agent A and an agent B in a ratio of (0.1-0.3) g: (2-5) mL; the agent A comprises nasal brain targeting peptide modified stem cell factor liposome freeze-dried powder and gel dry powder, the amino acid sequence of the nasal brain targeting peptide is as shown in SEQ ID NO.1, and the gel dry powder is formed by self-crosslinking mangiferin and rutin; and the agent B is a normal saline solution containing carboxymethyl chitosan. The targeted delivery preparation not only can meet long-time stable storage, but also can enhance the nasal-brain delivery efficiency of stem cell drugs. Besides, the targeted delivery preparation can be used independently or in combination with other treatment drugs, and is used for treating ischemic cerebral diseases, especially cerebral arterial thrombosis.

The invention discloses an engineered brain-targeted delivery cell as well as a preparation method and application thereof. The engineered brain-targeted delivery cell is prepared by carrying out modification treatment on the surface of the cell by using a modifier, wherein the modifier comprises a cationic material, alkaloid and / or polysaccharide. The method provided by the invention aims to overcome the problem that the cells are difficult to efficiently pass through the blood brain barrier (BBB) or effectively target the brain lesion site in the existing cell therapy. Through the above surface modification strategy, the tropism and retention ability of the modified cells to the brain microenvironment are significantly enhanced, so that the enrichment efficiency of the cells in the brain is improved. The modified cells obtained on the basis of the method are suitable for preparing drugs or cell preparations for treating various brain diseases. The brain diseases include but are not limited to cerebral apoplexy, Alzheimer's disease (AD), Parkinson's disease, brain tumor and the like. The method provides an important technical means for developing a novel and efficient brain disease cell treatment strategy, and has potential clinical application value.

The invention discloses an application of polygonatum odoratum-derived extracellular vesicle-like particles in preparation of cerebral ischemia reperfusion nerve injury protection drugs. The polygonatum odoratum-derived extracellular vesicle-like particle disclosed by the invention has the effects of promoting the cell viability of HT22 cells after OGD / R and reducing the apoptosis of the HT22 cells after OGD / R. In-vivo experiments show that the polygonatum odoratum-derived extracellular vesicle-like particles can reduce apoptosis of ischemic side brain cells after cerebral ischemia reperfusion of rats, reduce the cerebral infarction area and improve neuromotor dysfunction, and a new thought and basis are provided for developing drugs to treat cerebral apoplexy.